Cutaneous T-cell Lymphoma

Sep 19, 2023

FDA Approves Ojjaara for Myelofibrosis; EMA Grants PRIME Designation to Iopofosine I-131; EBGLYSS Receives Positive CHMP Opinion; FDA Accepts Resmetirom NDA; FDA Fast Track Designation to KT-333 for PTCL; RedHill Announces FDA sNDA Approval for Talicia®

Nov 11, 2022

How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle its Treatment Landscape

Oct 03, 2022

Insights Into The Cutaneous T-cell Lymphoma Treatment Market

Jul 08, 2019

Cutaneous T-cell lymphoma Market Outlook

Newsletter/Whitepaper